Saturday, October 3, 2026

EXCLUSIVE: Lennar’s Big New Customer Is Its Own Spinoff, Millrose

Lennar is selling homes to former spinoff Millrose, whose revenue largely comes from Lennar and whose largest voting shareholder is Lennar’s CEO.

MRP $3.8B

Hunterbrook Oct 2 2 clicks

Oct 2 IRDM $5B

Rocket Lab (NASDAQ: RKLB) Stock Rating: Accumulate After Q2 FY12/26 Earnings

Cestrian Capital Research

Oct 2 AIR $4B

Research & Analysis | AAR Corp. (NYSE: AIR): MRO Holdings Reshapes the Margin Profile

Monte Independent Investment Research 4 clicks

From X

@finphysnerd Sep 22 3 clicks

Myles on X

@HatfieldCapital @RealHerbHoover From what I've read $MMS has some exposure to va healthcare repricing as well. More importantly the rest of the business is lower quality. No defence/intelligence exposure, some segments overearning (natural disaster work and soft services volumes). Still looks cheap.

@BrokenMoats Sep 22 4 clicks

Broken Moats on X

Anyone have any suggestions how Muse and Grokbot and more versions to come of agent personal assistants is bullish of communication stocks like $RNG and $FIVN? Took out some of the intermediary businesses like $EVER and some pressure on $EXPE earlier in the day but seems next level is EXPE, some of the insurance brokers, and then phone communication systems seem at the top of losers from changing engagement and channels for B2C and B2B comms

@IdeaBrunchEmail Sep 22 2 clicks

Idea Brunch on X

Idea Brunch with David Polansky and Tim Delaney of Immersion Investments David and Tim break down their small-cap-focused research process and share commentary on $MAMA $SRTA and $RDVT Enjoy! https://t.co/zWh7qAOCoO

@P_Remarks Sep 22 3 clicks

Prepared Remarks on X

$MTCH bull case https://t.co/8iJYHVs7dl

@ClarkSquareCap Sep 22 1 click

Clark Square Capital on X

@valuedontlie $LUXE -- turnaround starting to bear fruit. Still egregiously cheap. https://t.co/oLMJf1s37V

@DOMOCAPITAL Sep 22

DOMO Capital Management, LLC on X

What makes $MNRO even more interesting is that short interest is ~22.5% of shares outstanding and 41% of the float as not only does Icahn have ~32% of shares tied up, but Gabelli (GAMCO) is also involved. This is probably why cost to borrow is so cheap. Shorts are betting on a dividend cut, but completely ignoring the fact that Icahn/Gabelli and others have 40%+ of the shares. Icahn is now flush with cash from the sale of Pep Boys to Mavis. He can either offer similar terms for $MNRO and buy the remaining shares for $25/share and come away with a superior asset vs Pep Boys or he can push for a sale of the entire company at a similar price or even more. Poison pill expires November 6th... going to get interesting. If there ends up being a proxy battle then all of these shares would have to be called back which would significantly increase short borrowing costs....

@TheBenSchmark Sep 22

JabroniCoin.USD on X

If Bernstein’s capex numbers for CXMT are anywhere in the ballpark, semicap ought to do well. At this point $ACMR seems to be still be a cheap hedge on memory https://t.co/b4lAZogFcJ https://t.co/kShCjd5m9x

@valuedontlie Sep 22

Colin King on X

$MDT $MMED exchange offer an interesting special sit… Own shares of MDT and swap for MMED at 7% discount Odd lot provision for 99 shares held too High enough share price to be worthwhile ($90+ MDT price works out to $600+ profit in a few weeks time)

The Trade Desk (NASDAQ: TTD) Stock Rating: Do Nothing After Q2 FY12/26 Earnings

The Trade Desk's Q2 revenue grew 3% to $715 million as Q3 guidance called for a year-over-year decline; TTD has fallen over 90% from its…

TTD $5.8B

Cestrian Capital Research Oct 2 1 click

Belden Inc.: The Ruckus Debt Looks Scarier Than The Math

Belden targets net leverage of 2.9x by 2027 from 3.9x, using RUCKUS's 65%+ gross margins and free cash flow to reduce debt.

BDC $4.3B

Lee Bailey Oct 2

Crocs: Double-Digit Buyback Yield (Ticker: CROX)

Crocs has $2 billion of buyback authorization, more than a third of its market cap, as North American sales stabilize and HeyDude drags on…

CROX $5.5B

Emerging Moats Research Oct 2 4 clicks

$TPB: can Turning Point Brands be the third player in nicotine pouches? | Saberpoint Capital

Turning Point Brands' FRE and Alp nicotine pouches aim to become a third C-store brand behind ZYN and Velo as PMTA rules limit new entrants.

TPB $1.1B

Yet Another Value Podcast Oct 1 2 clicks

How Ethos Sold Wall Street on AI While Powering an Analog Boiler Room

Ethos Technologies ($LIFE) sells AI-driven life insurance while relying heavily on multilevel marketing agencies using aggressive cold…

LIFE $2.2B

Hunterbrook Oct 1 1 click

Karman Holdings q2’26 Earnings Update

Karman Holdings reported 58% Q2 revenue growth, $1.3 billion backlog and margin expansion while replacing leadership and remediating…

KRMN $4.2B

Monte Independent Investment Research Oct 1

Innodata: The 45% Pullback Has Changed My View (Rating Upgrade)

Innodata's 45% pullback resets its valuation after two quarters of 50% revenue growth, though two customers still supply 71% of revenue and…

INOD $2.2B

Kurt Christensen Oct 1

This Week in Special Situations: Pearson, CarMax, Talen Energy, KBR, Apollo Commercial Real Estate

Pearson, CarMax, Talen Energy, KBR and Apollo Commercial Real Estate lead a 33-company survey of activist campaigns, buybacks, M&A and…

KMX $7.6B

Latticework by MOI Global Oct 1 1 click

Ladder Capital: Grab This Diversified, Investment-Grade Mortgage REIT At Below Book Value

Ladder Capital trades below book value with high yield, but faces margin pressure and office-loan exposure despite diversified funding and…

LADR $1.1B

Albert Anthony Oct 1

Group 1's CEO Said "Competitive Advantages and Opportunities." A Car Dealer? I Went Looking.

Group 1’s 19% ownership cap, tied to automaker franchise agreements, frames Conifer’s 1.9 million-share stake and potential buyback-driven…

GPI $2.8B

Cannibal Stocks Oct 1 1 click

AEGXF · long

Aecon Group Inc.

Aecon Group’s long thesis targets 50-80% share-price upside over 6-12 months as the company shifts beyond a complex special situation.

AEGXF $2.6B

Value Investors Club Jul 5 3 clicks

Not So Fast

Entravision, the portfolio’s largest position, fell more than 40% from its highs as Q3 returns dropped to 37.8% YTD.

EVC $634M

The Mikro Kap Oct 1 1 click

Q3 2026 Consolidated Holdings, Performance, and Ideas

Irrational Analysis reports 51.55% outperformance versus a semiconductor ETF, adding Credo for SerDes and QMCO for AI-driven tape storage…

QMCO $1.1B

Irrational Analysis Oct 1

NASDAQ:YB 10% dividend, 2x P/E, 30% growth, AI beneficiary, secular tailwinds, founder CEO I think is as good as Bezos/Walton

Yuanbao pairs a 10.2% dividend and cash exceeding its market value with 33.5% first-half profit growth from AI-enabled Chinese insurance…

YB $561M

Calvin Blissett Sep 30 4 clicks

Undercovered Dozen: Vicor, Rayonier, Accenture And More

Vicor, Rayonier, Accenture and nine other lesser-covered stocks make up Seeking Alpha’s Undercovered Dozen.

RYN $5.5B

The Undercovered Dozen Sep 30 4 clicks

3 Mergers and 1 Liquidation in the Danger Zone

Stratus Properties liquidates Austin real estate below projected distributions, while Atlantic Lithium and Intermex await approvals for…

IMXI $376M

Triple S Special Situations Investing Sep 30

Research Roundup Vol. LIV

Research Roundup covers AAON's data-center cooling ramp, Knife River's margin recovery, ChronoScale's Microsoft-backed neocloud buildout…

AAON $7.2BKNF $2.8B

Monte Independent Investment Research Sep 30

Sezzle: The Market Does Not See The Next Growth Phase

Sezzle’s Q2 revenue rose 51.7% as subscribers grew 76.4%, while SezzleCash and Sezzle Send add growth potential and greater underwriting…

SEZL $3.8B

Investor Overview Sep 30

Dark arts or infinite reload? $TTD’s CEO options and the repricing proxy

The Trade Desk’s CEO received a new 10-year option package targeting $105 per share as the company seeks shareholder approval to reprice…

TTD $5.8B

Yet Another Value Blog Sep 29 4 clicks

Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

Cullinan Therapeutics plans December 2026 autoimmune updates for CLN-978, while zipalertinib awaits an FDA decision in previously treated…

CGEM $1B

Myriam Alvarez Sep 29 2 clicks

Saturday, October 3, 2026

Myles on X

Broken Moats on X

Idea Brunch on X

Prepared Remarks on X

Clark Square Capital on X

DOMO Capital Management, LLC on X

JabroniCoin.USD on X

Colin King on X

Investor Letters

Publications we follow

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 218

X accounts we follow

Investor letters we follow

Sectors